REG - Beximco Pharmaceut - Board Changes

Beximco PharmaceuticalsAnnouncement

02/12/2020 11:05

RNS Number : 2809H
  
Beximco Pharmaceuticals Ltd
  
02 December 2020
  
 

2 December 2020
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
BEXIMCO PHARMACEUTICALS LTD. 
 
Board Changes
 
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces it has appointed Ms. Quamrun Naher Ahmed and Ms. Reem H. Shamsuddoha as Non-Executive Directors, with effect from 30 November 2020. 
 
Ms. Quamrun Naher Ahmed, before her retirement from service in the Bangladesh Government, worked in a number of different Government departments including Finance, Commerce, Shipping Fisheries and Livestock and Home Affairs.  In January 2014, Ms. Ahmed was appointed Additional Secretary:  Financial Institutions Division, Ministry of Finance of the Government of the People's Republic of Bangladesh. In March 2016, she was nominated as a Director of the Board of IFIC Bank Limited by the Ministry of Finance. Ms. Ahmed is a member of the Executive, Risk Management and the Nomination and Remuneration Committees of the Board of Directors of IFIC Bank Limited. She is also the Chairman of IFIC Securities Limited, a Director of IFIC Money Transfer (UK) Limited and Nepal Bangladesh Bank Limited, Nepal. 
 
Ms. Reem Shamsuddoha has a background in e-commerce and marketing having been educated in Bangladesh and attended Gabelli School of Business, Fordham University in New York.  She is Vice President at Dohatec New Media, an independent software vendor and technology firm developing solutions for clients in North America, Asia and Europe, as well as assisting in the rollout of E-Government procurement systems for four Government agencies in Bangladesh.
 
These Board appointments are in compliance with Notification No. BSEC/CMRRCD/2009-93/217/Admin/90 from the Bangladesh SEC, dated 21 May 2019, which requires that shareholders with aggregate shareholdings of at least 30 per cent of the shares in issue are represented on the Board and that all Directors must either hold 2 per cent of the shares each or represent a major shareholder (Sponsor). In order to comply with this new requirement by 30 November 2020, the timeframe set out by the Bangladesh SEC, the Company has appointed representatives of two of its shareholders as Non-Independent Non-Executive Directors.
 
Whilst the appointments are effective immediately, they remain subject to confirmation following completion of the required due diligence for UK regulatory purposes.  In accordance with the AIM Rules, the Company's nominated adviser has commenced its due diligence enquiries into Ms. Ahmed and Ms. Shamsuddoha and a further announcement will be made on the outcome of these enquiries once they have been completed.
 
 
Additional disclosure information
 
Ms. Quamrun Naher Ahmed
 
In addition to her appointment to the Board, Ms. Quamrun Naher Ahmed, aged 61, holds or has held the following directorships or partnerships in the past five years:
 



Current directorships/partnerships:
IFIC Bank Limited
IFIC Securities Ltd.
IFIC Money Transfer (UK) Ltd.
Nepal Bangladesh Bank Ltd.
 
 


Previous directorships/partnerships:
Karmasangsthan Bank 
 



Ms. Ahmed does not have any direct and indirect interest in the issued share capital of the Company but represents IFIC Bank Limited and IFIC Securities Limited.
 
Should the nominated adviser's due diligence enquiries be completed satisfactorily, then the appointment can be confirmed.  On confirmation, all disclosures to be made in accordance with Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Ms. Ahmed will then be made in a further announcement.
 
Ms. Reem H. Shamsuddoha 
 
In addition to her appointment to the Board, Ms. Shamsuddoha, aged 32, holds or has held the following directorships or partnerships in the past five years:
 



Current directorships/partnerships:
Global Voice Holdings Limited
Global Voice Telecom Limited
Beximco IOC Petroleum & Energy Limited
Bangladesh Export Import Co. Ltd
 


Previous directorships/partnerships:
None
 
 



 
Ms. Shamsuddoha does not have any direct and indirect interest in the issued share capital of the Company but represents the interests of Absolute Construction and Engineering Limited.
 
Should the nominated adviser's due diligence enquiries be completed satisfactorily, then the appointment can be confirmed.  On confirmation, all disclosures to be made in accordance with Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Ms. Shamsuddoha will then be made in a further announcement.
 
 
For further information please visit www.beximcopharma.com or enquire to: 
 



Beximco Pharma




Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
 




Mohammed Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, ext.20030
 




SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
 




SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 




FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
 



 
Notes to Editors
 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAUUVRRRKUURAA